Egen Luisa, Keller Karoline, Menold Hanna Saskia, Quan Allison, Dempfle Carl-Erik, Schoettler Jochen Johannes, Wessels Frederik, Meister Benjamin, Worst Thomas Stefan, Westhoff Niklas, Kriegmair Maximilian Christian, Honeck Patrick, Michel Maurice Stephan, Kowalewski Karl-Friedrich
Department of Urology and Urosurgery, Medical Faculty, University Medical Center Mannheim, Mannheim at Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
German Cancer Research Center (DKFZ) Heidelberg, Division of Intelligent Systems and Robotics in Urology (ISRU), Heidelberg, Germany.
World J Urol. 2024 Aug 8;42(1):477. doi: 10.1007/s00345-024-05168-x.
Radical cystectomy is associated with bleeding and high transfusion rates, presenting challenges in patient management. This study investigated the prophylactic use of tranexamic acid during radical cystectomy.
All consecutive patients treated with radical cystectomy at a tertiary care university center were included from a prospectively maintained database. After an institutional change in the cystectomy protocol patients received 1 g of intravenous bolus of tranexamic acid as prophylaxis. To prevent bias, propensity score matching was applied, accounting for differences in preoperative hemoglobin, neoadjuvant chemotherapy, tumor stage, and surgeon experience. Key outcomes included transfusion rates, complications, and occurrence of venous thromboembolism.
In total, 420 patients were included in the analysis, of whom 35 received tranexamic acid. After propensity score matching, 32 patients and 32 controls were matched with regard to clinicopathologic characteristics. Tranexamic acid significantly reduced the number of patients who received transfusions compared to controls (19% [95%-Confidence interval = 8.3; 37.1] vs. 47% [29.8; 64.8]; p = 0.033). Intraoperative and postoperative transfusion rates were lower with tranexamic acid, though not statistically significant (6% [1.5; 23.2] vs. 19% [8.3; 37.1], and 16% [6.3; 33.7] vs. 38% [21.9; 56.1]; p = 0.257 and p = 0.089, respectively). The occurrence of venous thromboembolism did not differ significantly between the groups (9% [2.9; 26.7] vs. 3% [0.4; 20.9]; p = 0.606).
Prophylactic tranexamic administration, using a simplified preoperative dosing regimen of 1 g as a bolus, significantly lowered the rate of blood transfusion after cystectomy. This exploratory study indicates the potential of tranexamic acid in enhancing outcomes of open radical cystectomy.
根治性膀胱切除术伴有出血和高输血率,给患者管理带来挑战。本研究调查了在根治性膀胱切除术中预防性使用氨甲环酸的情况。
从一个前瞻性维护的数据库中纳入了在一所三级医疗大学中心接受根治性膀胱切除术的所有连续患者。在膀胱切除术方案发生机构性变更后,患者接受1克静脉推注氨甲环酸作为预防措施。为防止偏差,采用倾向评分匹配,考虑术前血红蛋白、新辅助化疗、肿瘤分期和外科医生经验的差异。主要结局包括输血率、并发症和静脉血栓栓塞的发生情况。
总共420例患者纳入分析,其中35例接受了氨甲环酸治疗。经过倾向评分匹配后,32例患者和32例对照在临床病理特征方面相匹配。与对照组相比,氨甲环酸显著降低了接受输血的患者数量(19%[95%置信区间=8.3;37.1]对47%[29.8;64.8];p=0.033)。氨甲环酸组的术中和术后输血率较低,尽管无统计学意义(6%[1.5;23.2]对19%[8.3;37.1],以及16%[6.3;33.7]对38%[21.9;56.1];p分别为0.257和0.089)。两组之间静脉血栓栓塞的发生率无显著差异(9%[2.9;26.7]对3%[0.4;20.9];p=0.606)。
采用1克推注的简化术前给药方案预防性给予氨甲环酸,显著降低了膀胱切除术后的输血率。这项探索性研究表明氨甲环酸在改善开放性根治性膀胱切除术结局方面的潜力。